Non-invasive Blood Tests Hold Promise for Transplant Outcomes

transplant recipients in the fi rst year post-transplant are infection and rejection. Over time, transplant coronary artery disease (a form of chronic rejection) and malignancy (resulting from inadequate immune surveillance of cancer cells) emerge as threats. Balancing immune response is one of the most serious challenges for the transplant cardiologist: over-immunosuppression results in an increased risk for infection and malignancy, while under-immunosuppression results in increased risk for rejection and transplant CAD.